Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Bluejay Diagnostics (BJDX) Short-Term Debt issuances (2021)

Bluejay Diagnostics recorded quarterly Short-Term Debt issuances of $725.0 in Q2 2021, up 107.46% quarter-over-quarter from -$9725.0 in Q1 2021.

Bluejay Diagnostics' Short-Term Debt issuances history runs 1 years deep, the most recent figure standing at $725.0 for Q2 2021.

  • In Q2 2021, Short-Term Debt issuances changed N/A year-over-year to $725.0; the TTM figure through Dec 2021 stood at -$9000.0 (changed N/A YoY), while the FY2021 annual figure was -$9000.0, down 107.76% from the prior year.
  • Short-Term Debt issuances came in at $725.0 for Q2 2021 at Bluejay Diagnostics, up from -$9725.0 in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $725.0 in Q2 2021 to a low of -$9725.0 in Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 31.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -1.23 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -1.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 37.80 Mn
10 Bluejay Diagnostics 572,394.44 -3.11 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2021 725.00
Jun 30, 2021 725.00
Mar 31, 2021 -9,725.00
Mar 31, 2021 -9,725.00